APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGF Inhibitors for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global VEGF Inhibitors for Cancer Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchVEGF Inhibitors for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGF Inhibitors for Cancer Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal VEGF Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGF Inhibitors for Cancer Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGF Inhibitors for Cancer Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global VEGF Inhibitors for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for VEGF Inhibitors for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for VEGF Inhibitors for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for VEGF Inhibitors for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for VEGF Inhibitors for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of VEGF Inhibitors for Cancer include Amgen, Amneal Pharmaceuticals, Celltrion Healthcare, Eli Lilly, Pfizer, Roche, Sanofi, Boan Biotech and Jiangsu Hengrui Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for VEGF Inhibitors for Cancer, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of VEGF Inhibitors for Cancer, also provides the sales of main regions and countries. Of the upcoming market potential for VEGF Inhibitors for Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the VEGF Inhibitors for Cancer sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global VEGF Inhibitors for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for VEGF Inhibitors for Cancer sales, projected growth trends, production technology, application and end-user industry.

VEGF Inhibitors for Cancer Segment by Company

Amgen

Amneal Pharmaceuticals

Celltrion Healthcare

Eli Lilly

Pfizer

Roche

Sanofi

Boan Biotech

Jiangsu Hengrui Pharmaceuticals

Qilu Pharma

SinoCellTech

Innovent

Chia Tai Tianqing

VEGF Inhibitors for Cancer Segment by Type

Ramucirumab

Ramucirumab

Aflibercept

Other

VEGF Inhibitors for Cancer Segment by Application

Metastatic colorectal cancer

Metastatic Non-small Cell Lung Cancer

Cervical Cancer

Recurrent Glioblastoma

Other

VEGF Inhibitors for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Inhibitors for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGF Inhibitors for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Inhibitors for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of VEGF Inhibitors for Cancer in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of VEGF Inhibitors for Cancer manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, VEGF Inhibitors for Cancer sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ramucirumab Major Manufacturers Table 3. Ramucirumab Major Manufacturers Table 4. Aflibercept Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Metastatic colorectal cancer Major Manufacturers Table 8. Metastatic Non-small Cell Lung Cancer Major Manufacturers Table 9. Cervical Cancer Major Manufacturers Table 10. Recurrent Glioblastoma Major Manufacturers Table 11. Other Major Manufacturers Table 12. VEGF Inhibitors for Cancer Industry Trends Table 13. VEGF Inhibitors for Cancer Industry Drivers Table 14. VEGF Inhibitors for Cancer Industry Opportunities and Challenges Table 15. VEGF Inhibitors for Cancer Industry Restraints Table 16. Global VEGF Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global VEGF Inhibitors for Cancer Revenue by Region (2021-2026) & (US$ Million) Table 18. Global VEGF Inhibitors for Cancer Revenue by Region (2027-2032) & (US$ Million) Table 19. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021-2026) Table 20. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2027-2032) Table 21. Global VEGF Inhibitors for Cancer Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global VEGF Inhibitors for Cancer Sales by Region (2021-2026) & (K Units) Table 23. Global VEGF Inhibitors for Cancer Sales by Region (2027-2032) & (K Units) Table 24. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021-2026) Table 25. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2027-2032) Table 26. Global VEGF Inhibitors for Cancer Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global VEGF Inhibitors for Cancer Revenue Market Share by Manufacturers (2021-2026) Table 28. Global VEGF Inhibitors for Cancer Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021-2026) Table 30. Global VEGF Inhibitors for Cancer Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global VEGF Inhibitors for Cancer Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global VEGF Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global VEGF Inhibitors for Cancer Manufacturers, Product Type & Application Table 34. Global VEGF Inhibitors for Cancer Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global VEGF Inhibitors for Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global VEGF Inhibitors for Cancer Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 39. Global VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 40. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2026) Table 41. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2027-2032) Table 42. Global VEGF Inhibitors for Cancer Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 44. Global VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 45. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2026) Table 46. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2027-2032) Table 47. Global VEGF Inhibitors for Cancer Price by Type (2021-2026) & (US$/Unit) Table 48. Global VEGF Inhibitors for Cancer Price by Type (2027-2032) & (US$/Unit) Table 49. Global VEGF Inhibitors for Cancer Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 51. Global VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 52. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2026) Table 53. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2027-2032) Table 54. Global VEGF Inhibitors for Cancer Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 56. Global VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 57. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2026) Table 58. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2027-2032) Table 59. Global VEGF Inhibitors for Cancer Price by Application (2021-2026) & (US$/Unit) Table 60. Global VEGF Inhibitors for Cancer Price by Application (2027-2032) & (US$/Unit) Table 61. Amgen Company Information Table 62. Amgen Business Overview Table 63. Amgen VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Amgen VEGF Inhibitors for Cancer Product Portfolio Table 65. Amgen Recent Development Table 66. Amneal Pharmaceuticals Company Information Table 67. Amneal Pharmaceuticals Business Overview Table 68. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio Table 70. Amneal Pharmaceuticals Recent Development Table 71. Celltrion Healthcare Company Information Table 72. Celltrion Healthcare Business Overview Table 73. Celltrion Healthcare VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio Table 75. Celltrion Healthcare Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Eli Lilly VEGF Inhibitors for Cancer Product Portfolio Table 80. Eli Lilly Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Pfizer VEGF Inhibitors for Cancer Product Portfolio Table 85. Pfizer Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Roche VEGF Inhibitors for Cancer Product Portfolio Table 90. Roche Recent Development Table 91. Sanofi Company Information Table 92. Sanofi Business Overview Table 93. Sanofi VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sanofi VEGF Inhibitors for Cancer Product Portfolio Table 95. Sanofi Recent Development Table 96. Boan Biotech Company Information Table 97. Boan Biotech Business Overview Table 98. Boan Biotech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Boan Biotech VEGF Inhibitors for Cancer Product Portfolio Table 100. Boan Biotech Recent Development Table 101. Jiangsu Hengrui Pharmaceuticals Company Information Table 102. Jiangsu Hengrui Pharmaceuticals Business Overview Table 103. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio Table 105. Jiangsu Hengrui Pharmaceuticals Recent Development Table 106. Qilu Pharma Company Information Table 107. Qilu Pharma Business Overview Table 108. Qilu Pharma VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio Table 110. Qilu Pharma Recent Development Table 111. SinoCellTech Company Information Table 112. SinoCellTech Business Overview Table 113. SinoCellTech VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. SinoCellTech VEGF Inhibitors for Cancer Product Portfolio Table 115. SinoCellTech Recent Development Table 116. Innovent Company Information Table 117. Innovent Business Overview Table 118. Innovent VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Innovent VEGF Inhibitors for Cancer Product Portfolio Table 120. Innovent Recent Development Table 121. Chia Tai Tianqing Company Information Table 122. Chia Tai Tianqing Business Overview Table 123. Chia Tai Tianqing VEGF Inhibitors for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio Table 125. Chia Tai Tianqing Recent Development Table 126. North America VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 127. North America VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 128. North America VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 129. North America VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 130. North America VEGF Inhibitors for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 131. North America VEGF Inhibitors for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 132. North America VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 133. North America VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 134. North America VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 135. North America VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 136. North America VEGF Inhibitors for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 137. North America VEGF Inhibitors for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 138. North America VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. North America VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 140. North America VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 141. North America VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 142. North America VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 143. North America VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 144. North America VEGF Inhibitors for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 145. North America VEGF Inhibitors for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 146. United States VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 147. Canada VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 148. Mexico VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 149. Europe VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 150. Europe VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 151. Europe VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 152. Europe VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 153. Europe VEGF Inhibitors for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 154. Europe VEGF Inhibitors for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 155. Europe VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 156. Europe VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 157. Europe VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 158. Europe VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 159. Europe VEGF Inhibitors for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 160. Europe VEGF Inhibitors for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 161. Europe VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Europe VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Europe VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Europe VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 165. Europe VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 166. Europe VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 167. Europe VEGF Inhibitors for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 168. Europe VEGF Inhibitors for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 169. Germany VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 170. France VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 171. U.K. VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 172. Italy VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 173. Russia VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 174. Spain VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 175. Netherlands VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 176. Switzerland VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 177. Sweden VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 178. Poland VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 179. China VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 180. China VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 181. China VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 182. China VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 183. China VEGF Inhibitors for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 184. China VEGF Inhibitors for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 185. China VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 186. China VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 187. China VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 188. China VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 189. China VEGF Inhibitors for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 190. China VEGF Inhibitors for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 191. Asia VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 192. Asia VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 193. Asia VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 194. Asia VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 195. Asia VEGF Inhibitors for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 196. Asia VEGF Inhibitors for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 197. Asia VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 198. Asia VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 199. Asia VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 200. Asia VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 201. Asia VEGF Inhibitors for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 202. Asia VEGF Inhibitors for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 203. Asia VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. Asia VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 205. Asia VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 206. Asia VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 207. Asia VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 208. Asia VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 209. Asia VEGF Inhibitors for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 210. Asia VEGF Inhibitors for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 211. Japan VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 212. South Korea VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 213. India VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 214. Australia VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 215. Taiwan VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 216. Southeast Asia VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 217. SAMEA VEGF Inhibitors for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 218. SAMEA VEGF Inhibitors for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 219. SAMEA VEGF Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 220. SAMEA VEGF Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 221. SAMEA VEGF Inhibitors for Cancer Sales Price by Type (2021-2026) & (US$/Unit) Table 222. SAMEA VEGF Inhibitors for Cancer Sales Price by Type (2027-2032) & (US$/Unit) Table 223. SAMEA VEGF Inhibitors for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 224. SAMEA VEGF Inhibitors for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 225. SAMEA VEGF Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 226. SAMEA VEGF Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 227. SAMEA VEGF Inhibitors for Cancer Sales Price by Application (2021-2026) & (US$/Unit) Table 228. SAMEA VEGF Inhibitors for Cancer Sales Price by Application (2027-2032) & (US$/Unit) Table 229. SAMEA VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 230. SAMEA VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 231. SAMEA VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 232. SAMEA VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 233. SAMEA VEGF Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 234. SAMEA VEGF Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 235. SAMEA VEGF Inhibitors for Cancer Sales Price by Country (2021-2026) & (US$/Unit) Table 236. SAMEA VEGF Inhibitors for Cancer Sales Price by Country (2027-2032) & (US$/Unit) Table 237. Brazil VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 238. Argentina VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 239. Chile VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 240. Colombia VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 241. Peru VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 242. Saudi Arabia VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 243. Israel VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 244. UAE VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 245. Turkey VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 246. Iran VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 247. Egypt VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Table 248. Key Raw Materials Table 249. Raw Materials Key Suppliers Table 250. VEGF Inhibitors for Cancer Distributors List Table 251. VEGF Inhibitors for Cancer Customers List Table 252. Research Programs/Design for This Report Table 253. Authors List of This Report Table 254. Secondary Sources Table 255. Primary Sources List of Figures Figure 1. VEGF Inhibitors for Cancer Image Figure 2. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGF Inhibitors for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ramucirumab Image Figure 5. Ramucirumab Image Figure 6. Aflibercept Image Figure 7. Other Image Figure 8. Global VEGF Inhibitors for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global VEGF Inhibitors for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 10. Metastatic colorectal cancer Image Figure 11. Metastatic Non-small Cell Lung Cancer Image Figure 12. Cervical Cancer Image Figure 13. Recurrent Glioblastoma Image Figure 14. Other Image Figure 15. Global VEGF Inhibitors for Cancer Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global VEGF Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 17. Global VEGF Inhibitors for Cancer Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global VEGF Inhibitors for Cancer Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021-2032) Figure 20. Global VEGF Inhibitors for Cancer Sales (2021-2032) & (K Units) Figure 21. Global VEGF Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico VEGF Inhibitors for Cancer Sales YoY (2021-2032) & (K Units) Figure 24. Europe VEGF Inhibitors for Cancer Sales YoY (2021-2032) & (K Units) Figure 25. China VEGF Inhibitors for Cancer Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) VEGF Inhibitors for Cancer Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa VEGF Inhibitors for Cancer Sales YoY (2021-2032) & (K Units) Figure 28. Global VEGF Inhibitors for Cancer Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global VEGF Inhibitors for Cancer Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global VEGF Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global VEGF Inhibitors for Cancer Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2032) Figure 34. Global VEGF Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global VEGF Inhibitors for Cancer Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2032) Figure 37. Global VEGF Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global VEGF Inhibitors for Cancer Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2032) Figure 40. Global VEGF Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global VEGF Inhibitors for Cancer Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2032) Figure 43. North America VEGF Inhibitors for Cancer Revenue Share by Type (2021-2032) Figure 44. North America VEGF Inhibitors for Cancer Sales Share by Type (2021-2032) Figure 45. North America VEGF Inhibitors for Cancer Revenue Share by Application (2021-2032) Figure 46. North America VEGF Inhibitors for Cancer Sales Share by Application (2021-2032) Figure 47. North America VEGF Inhibitors for Cancer Revenue Share by Country (2021-2032) Figure 48. North America VEGF Inhibitors for Cancer Sales Share by Country (2021-2032) Figure 49. Europe VEGF Inhibitors for Cancer Revenue Share by Type (2021-2032) Figure 50. Europe VEGF Inhibitors for Cancer Sales Share by Type (2021-2032) Figure 51. Europe VEGF Inhibitors for Cancer Revenue Share by Application (2021-2032) Figure 52. Europe VEGF Inhibitors for Cancer Sales Share by Application (2021-2032) Figure 53. Europe VEGF Inhibitors for Cancer Revenue Share by Country (2021-2032) Figure 54. Europe VEGF Inhibitors for Cancer Sales Share by Country (2021-2032) Figure 55. China VEGF Inhibitors for Cancer Revenue Share by Type (2021-2032) Figure 56. China VEGF Inhibitors for Cancer Sales Share by Type (2021-2032) Figure 57. China VEGF Inhibitors for Cancer Revenue Share by Application (2021-2032) Figure 58. China VEGF Inhibitors for Cancer Sales Share by Application (2021-2032) Figure 59. Asia VEGF Inhibitors for Cancer Revenue Share by Type (2021-2032) Figure 60. Asia VEGF Inhibitors for Cancer Sales Share by Type (2021-2032) Figure 61. Asia VEGF Inhibitors for Cancer Revenue Share by Application (2021-2032) Figure 62. Asia VEGF Inhibitors for Cancer Sales Share by Application (2021-2032) Figure 63. Asia VEGF Inhibitors for Cancer Revenue Share by Country (2021-2032) Figure 64. Asia VEGF Inhibitors for Cancer Sales Share by Country (2021-2032) Figure 65. SAMEA VEGF Inhibitors for Cancer Revenue Share by Type (2021-2032) Figure 66. SAMEA VEGF Inhibitors for Cancer Sales Share by Type (2021-2032) Figure 67. SAMEA VEGF Inhibitors for Cancer Revenue Share by Application (2021-2032) Figure 68. SAMEA VEGF Inhibitors for Cancer Sales Share by Application (2021-2032) Figure 69. SAMEA VEGF Inhibitors for Cancer Revenue Share by Country (2021-2032) Figure 70. SAMEA VEGF Inhibitors for Cancer Sales Share by Country (2021-2032) Figure 71. VEGF Inhibitors for Cancer Value Chain Figure 72. Manufacturing Cost Structure Figure 73. VEGF Inhibitors for Cancer Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Ramucirumab
  • Ramucirumab
  • Aflibercept
  • Other
Applications
  • Metastatic colorectal cancer
  • Metastatic Non-small Cell Lung Cancer
  • Cervical Cancer
  • Recurrent Glioblastoma
  • Other
Companies covered
  • Amgen
  • Amneal Pharmaceuticals
  • Celltrion Healthcare
  • Eli Lilly
  • Pfizer
  • Roche
  • Sanofi
  • Boan Biotech
  • Jiangsu Hengrui Pharmaceuticals
  • Qilu Pharma
  • SinoCellTech
  • Innovent
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 VEGF Inhibitors for Cancer Market by Type
  3. 1.2.1 Global VEGF Inhibitors for Cancer Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ramucirumab
  5. 1.2.3 Ramucirumab
  6. 1.2.4 Aflibercept
  7. 1.2.5 Other
  8. 1.3 VEGF Inhibitors for Cancer Market by Application
  9. 1.3.1 Global VEGF Inhibitors for Cancer Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Metastatic colorectal cancer
  11. 1.3.3 Metastatic Non-small Cell Lung Cancer
  12. 1.3.4 Cervical Cancer
  13. 1.3.5 Recurrent Glioblastoma
  14. 1.3.6 Other
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 VEGF Inhibitors for Cancer Market Dynamics
  1. 2.1 VEGF Inhibitors for Cancer Industry Trends
  2. 2.2 VEGF Inhibitors for Cancer Industry Drivers
  3. 2.3 VEGF Inhibitors for Cancer Industry Opportunities and Challenges
  4. 2.4 VEGF Inhibitors for Cancer Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global VEGF Inhibitors for Cancer Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global VEGF Inhibitors for Cancer Revenue by Region
  3. 3.2.1 Global VEGF Inhibitors for Cancer Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global VEGF Inhibitors for Cancer Revenue by Region (2021-2026)
  5. 3.2.3 Global VEGF Inhibitors for Cancer Revenue by Region (2027-2032)
  6. 3.2.4 Global VEGF Inhibitors for Cancer Revenue Market Share by Region (2021-2032)
  7. 3.3 Global VEGF Inhibitors for Cancer Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global VEGF Inhibitors for Cancer Sales by Region
  9. 3.4.1 Global VEGF Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global VEGF Inhibitors for Cancer Sales by Region (2021-2026)
  11. 3.4.3 Global VEGF Inhibitors for Cancer Sales by Region (2027-2032)
  12. 3.4.4 Global VEGF Inhibitors for Cancer Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global VEGF Inhibitors for Cancer Revenue by Manufacturers
  2. 4.1.1 Global VEGF Inhibitors for Cancer Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global VEGF Inhibitors for Cancer Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global VEGF Inhibitors for Cancer Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global VEGF Inhibitors for Cancer Sales by Manufacturers
  6. 4.2.1 Global VEGF Inhibitors for Cancer Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global VEGF Inhibitors for Cancer Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global VEGF Inhibitors for Cancer Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global VEGF Inhibitors for Cancer Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global VEGF Inhibitors for Cancer Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global VEGF Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global VEGF Inhibitors for Cancer Manufacturers, Product Type & Application
  13. 4.7 Global VEGF Inhibitors for Cancer Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global VEGF Inhibitors for Cancer Market CR5 and HHI
  16. 4.8.2 2025 VEGF Inhibitors for Cancer Tier 1, Tier 2, and Tier 3
5 VEGF Inhibitors for Cancer Market by Type
  1. 5.1 Global VEGF Inhibitors for Cancer Revenue by Type
  2. 5.1.1 Global VEGF Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global VEGF Inhibitors for Cancer Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Type (2021-2032)
  5. 5.2 Global VEGF Inhibitors for Cancer Sales by Type
  6. 5.2.1 Global VEGF Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VEGF Inhibitors for Cancer Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global VEGF Inhibitors for Cancer Sales Market Share by Type (2021-2032)
  9. 5.3 Global VEGF Inhibitors for Cancer Price by Type
6 VEGF Inhibitors for Cancer Market by Application
  1. 6.1 Global VEGF Inhibitors for Cancer Revenue by Application
  2. 6.1.1 Global VEGF Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global VEGF Inhibitors for Cancer Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global VEGF Inhibitors for Cancer Revenue Market Share by Application (2021-2032)
  5. 6.2 Global VEGF Inhibitors for Cancer Sales by Application
  6. 6.2.1 Global VEGF Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global VEGF Inhibitors for Cancer Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global VEGF Inhibitors for Cancer Sales Market Share by Application (2021-2032)
  9. 6.3 Global VEGF Inhibitors for Cancer Price by Application
7 Company Profiles
  1. 7.1 Amgen
  2. 7.1.1 Amgen Company Information
  3. 7.1.2 Amgen Business Overview
  4. 7.1.3 Amgen VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Amgen VEGF Inhibitors for Cancer Product Portfolio
  6. 7.1.5 Amgen Recent Developments
  7. 7.2 Amneal Pharmaceuticals
  8. 7.2.1 Amneal Pharmaceuticals Company Information
  9. 7.2.2 Amneal Pharmaceuticals Business Overview
  10. 7.2.3 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amneal Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
  12. 7.2.5 Amneal Pharmaceuticals Recent Developments
  13. 7.3 Celltrion Healthcare
  14. 7.3.1 Celltrion Healthcare Company Information
  15. 7.3.2 Celltrion Healthcare Business Overview
  16. 7.3.3 Celltrion Healthcare VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Celltrion Healthcare VEGF Inhibitors for Cancer Product Portfolio
  18. 7.3.5 Celltrion Healthcare Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly VEGF Inhibitors for Cancer Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer VEGF Inhibitors for Cancer Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Roche VEGF Inhibitors for Cancer Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Sanofi
  38. 7.7.1 Sanofi Company Information
  39. 7.7.2 Sanofi Business Overview
  40. 7.7.3 Sanofi VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi VEGF Inhibitors for Cancer Product Portfolio
  42. 7.7.5 Sanofi Recent Developments
  43. 7.8 Boan Biotech
  44. 7.8.1 Boan Biotech Company Information
  45. 7.8.2 Boan Biotech Business Overview
  46. 7.8.3 Boan Biotech VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Boan Biotech VEGF Inhibitors for Cancer Product Portfolio
  48. 7.8.5 Boan Biotech Recent Developments
  49. 7.9 Jiangsu Hengrui Pharmaceuticals
  50. 7.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 7.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 7.9.3 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Hengrui Pharmaceuticals VEGF Inhibitors for Cancer Product Portfolio
  54. 7.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 7.10 Qilu Pharma
  56. 7.10.1 Qilu Pharma Company Information
  57. 7.10.2 Qilu Pharma Business Overview
  58. 7.10.3 Qilu Pharma VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Qilu Pharma VEGF Inhibitors for Cancer Product Portfolio
  60. 7.10.5 Qilu Pharma Recent Developments
  61. 7.11 SinoCellTech
  62. 7.11.1 SinoCellTech Company Information
  63. 7.11.2 SinoCellTech Business Overview
  64. 7.11.3 SinoCellTech VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 SinoCellTech VEGF Inhibitors for Cancer Product Portfolio
  66. 7.11.5 SinoCellTech Recent Developments
  67. 7.12 Innovent
  68. 7.12.1 Innovent Company Information
  69. 7.12.2 Innovent Business Overview
  70. 7.12.3 Innovent VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Innovent VEGF Inhibitors for Cancer Product Portfolio
  72. 7.12.5 Innovent Recent Developments
  73. 7.13 Chia Tai Tianqing
  74. 7.13.1 Chia Tai Tianqing Company Information
  75. 7.13.2 Chia Tai Tianqing Business Overview
  76. 7.13.3 Chia Tai Tianqing VEGF Inhibitors for Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Chia Tai Tianqing VEGF Inhibitors for Cancer Product Portfolio
  78. 7.13.5 Chia Tai Tianqing Recent Developments
8 North America
  1. 8.1 North America VEGF Inhibitors for Cancer Market Size by Type
  2. 8.1.1 North America VEGF Inhibitors for Cancer Revenue by Type (2021-2032)
  3. 8.1.2 North America VEGF Inhibitors for Cancer Sales by Type (2021-2032)
  4. 8.1.3 North America VEGF Inhibitors for Cancer Price by Type (2021-2032)
  5. 8.2 North America VEGF Inhibitors for Cancer Market Size by Application
  6. 8.2.1 North America VEGF Inhibitors for Cancer Revenue by Application (2021-2032)
  7. 8.2.2 North America VEGF Inhibitors for Cancer Sales by Application (2021-2032)
  8. 8.2.3 North America VEGF Inhibitors for Cancer Price by Application (2021-2032)
  9. 8.3 North America VEGF Inhibitors for Cancer Market Size by Country
  10. 8.3.1 North America VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America VEGF Inhibitors for Cancer Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe VEGF Inhibitors for Cancer Market Size by Type
  2. 9.1.1 Europe VEGF Inhibitors for Cancer Revenue by Type (2021-2032)
  3. 9.1.2 Europe VEGF Inhibitors for Cancer Sales by Type (2021-2032)
  4. 9.1.3 Europe VEGF Inhibitors for Cancer Price by Type (2021-2032)
  5. 9.2 Europe VEGF Inhibitors for Cancer Market Size by Application
  6. 9.2.1 Europe VEGF Inhibitors for Cancer Revenue by Application (2021-2032)
  7. 9.2.2 Europe VEGF Inhibitors for Cancer Sales by Application (2021-2032)
  8. 9.2.3 Europe VEGF Inhibitors for Cancer Price by Application (2021-2032)
  9. 9.3 Europe VEGF Inhibitors for Cancer Market Size by Country
  10. 9.3.1 Europe VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe VEGF Inhibitors for Cancer Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China VEGF Inhibitors for Cancer Market Size by Type
  2. 10.1.1 China VEGF Inhibitors for Cancer Revenue by Type (2021-2032)
  3. 10.1.2 China VEGF Inhibitors for Cancer Sales by Type (2021-2032)
  4. 10.1.3 China VEGF Inhibitors for Cancer Price by Type (2021-2032)
  5. 10.2 China VEGF Inhibitors for Cancer Market Size by Application
  6. 10.2.1 China VEGF Inhibitors for Cancer Revenue by Application (2021-2032)
  7. 10.2.2 China VEGF Inhibitors for Cancer Sales by Application (2021-2032)
  8. 10.2.3 China VEGF Inhibitors for Cancer Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia VEGF Inhibitors for Cancer Market Size by Type
  2. 11.1.1 Asia VEGF Inhibitors for Cancer Revenue by Type (2021-2032)
  3. 11.1.2 Asia VEGF Inhibitors for Cancer Sales by Type (2021-2032)
  4. 11.1.3 Asia VEGF Inhibitors for Cancer Price by Type (2021-2032)
  5. 11.2 Asia VEGF Inhibitors for Cancer Market Size by Application
  6. 11.2.1 Asia VEGF Inhibitors for Cancer Revenue by Application (2021-2032)
  7. 11.2.2 Asia VEGF Inhibitors for Cancer Sales by Application (2021-2032)
  8. 11.2.3 Asia VEGF Inhibitors for Cancer Price by Application (2021-2032)
  9. 11.3 Asia VEGF Inhibitors for Cancer Market Size by Country
  10. 11.3.1 Asia VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia VEGF Inhibitors for Cancer Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA VEGF Inhibitors for Cancer Market Size by Type
  2. 12.1.1 SAMEA VEGF Inhibitors for Cancer Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA VEGF Inhibitors for Cancer Sales by Type (2021-2032)
  4. 12.1.3 SAMEA VEGF Inhibitors for Cancer Price by Type (2021-2032)
  5. 12.2 SAMEA VEGF Inhibitors for Cancer Market Size by Application
  6. 12.2.1 SAMEA VEGF Inhibitors for Cancer Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA VEGF Inhibitors for Cancer Sales by Application (2021-2032)
  8. 12.2.3 SAMEA VEGF Inhibitors for Cancer Price by Application (2021-2032)
  9. 12.3 SAMEA VEGF Inhibitors for Cancer Market Size by Country
  10. 12.3.1 SAMEA VEGF Inhibitors for Cancer Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA VEGF Inhibitors for Cancer Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA VEGF Inhibitors for Cancer Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 VEGF Inhibitors for Cancer Value Chain Analysis
  2. 13.1.1 VEGF Inhibitors for Cancer Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 VEGF Inhibitors for Cancer Production Mode & Process
  6. 13.2 VEGF Inhibitors for Cancer Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 VEGF Inhibitors for Cancer Distributors
  9. 13.2.3 VEGF Inhibitors for Cancer Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst